Corrigendum to “Chemokines and heart disease: A network connecting cardiovascular biology to immune and autonomic nervous systems” (Mediators Inflamm (2016) 2016, (5902947) DOI: 10.1155/2016/5902947;Chemokines and Heart Disease: A Network Connecting Cardiovascular Biology to Immune and Autonomic Nervous Systems

Mediators of Inflammation

Volumn 2016, Issue , 2016, Pages

  Dusi, Veronica ^a   Ghidoni, Alice ^b,c   Ravera, Alice ^d   De Ferrari, Gaetano M ^a,c   Calvillo, Laura ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d University and Civil Hospital of Brescia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CARBON TETRACHLORIDE; CHEMOKINE; CXCL1 CHEMOKINE; CXCL13 CHEMOKINE; CXCL16 CHEMOKINE; CXCL2 CHEMOKINE; CXCL9 CHEMOKINE; CYCLIC GMP; EOTAXIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR 4;

AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CELL INFILTRATION; CLINICAL PRACTICE; CONGESTIVE CARDIOMYOPATHY; CYTOKINE PRODUCTION; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNE SYSTEM; INNATE IMMUNITY; ISCHEMIC CARDIOMYOPATHY; MAST CELL; MOLECULAR INTERACTION; NONHUMAN; REVIEW; ANIMAL; CARDIOVASCULAR DISEASE; IMMUNOLOGY; METABOLISM; RISK FACTOR;

ANIMALS; AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR DISEASES; CHEMOKINES; HEART DISEASES; HUMANS; RISK FACTORS;

EID: 84971278423     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2018/4128049     Document Type: Erratum

References (138)

1. H. Nomiyama, N. Osada, and O. Yoshie, "The evolution of mammalian chemokine genes, " Cytokine and Growth Factor Reviews, vol. 21, no. 4, pp. 253-262, 2010.
2. J. E. Pease and T. J. Williams, "The attraction of chemokines as a target for specific anti-inflammatory therapy, " British Journal of Pharmacology, vol. 147, supplement 1, pp. S212-S221, 2006.
3. A. R. Bradshaw and E. A. Dennis, Handbook of Cell Signaling, Three-Volume Set, Academic Press, Cambridge, Mass, USA, 2003.
4. X. Blanchet, M. Langer, C. Weber, R. Koenen, and P. von Hundelshausen, "Touch of chemokines, " Frontiers in Immunology, vol. 3, article 175, 2012.
5. C. A. Gleissner, I. Shaked, C. Erbel, D. Böckler, H. A. Katus, and K. Ley, "CXCL4 downregulates the atheroprotective hemoglobin receptor CD163 in human macrophages, " Circulation Research, vol. 106, no. 1, pp. 203-211, 2010.
6. T. O. Nossuli, N. G. Frangogiannis, P. Knuefermann et al., "Brief murine myocardial I/R induces chemokines in a TNF-independent manner: role of oxygen radicals, " American Journal of Physiology-Heart and Circulatory Physiology, vol. 281, no. 6, pp. H2549-H2558, 2001.
7. F. Montecucco, V. Braunersreuther, S. Lenglet et al., "CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice, " European Heart Journal, vol. 33, no. 15, pp. 1964-1974, 2012.
8. P. Libby, "Inflammation and cardiovascular disease mechanisms, " The American Journal of Clinical Nutrition, vol. 83, no. 2, pp. 456S-460S, 2006.
9. V. Braunersreuther, F. Montecucco, G. Pelli et al., "Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarctionmyocardial injury and survival in mice, " Thrombosis and Haemostasis, vol. 110, no. 4, pp. 807-825, 2013.
10. N. G. Frangogiannis, K. A. Youker, R. D. Rossen et al., "Cytokines and the microcirculation in ischemia and reperfusion, " Journal of Molecular and Cellular Cardiology, vol. 30, no. 12, pp. 2567-2576, 1998.
11. P. Kong, P. Christia, and N. G. Frangogiannis, "The pathogenesis of cardiac fibrosis, " Cellular and Molecular Life Sciences, vol. 71, no. 4, pp. 549-574, 2014.
12. G. L. Kukielka, C. W. Smith, G. J. LaRosa et al., "Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo, "The Journal of Clinical Investigation, vol. 95, no. 1, pp. 89-103, 1995.
13. B. Chandrasekar, J. B. Smith, and G. L. Freeman, "Ischemiareperfusion of rat myocardium activates nuclear factor-b and induces neutrophil infiltration via lipopolysaccharide-induced CXC chemokine, " Circulation, vol. 103, no. 18, pp. 2296-2302, 2001.
14. E. Elmas, S. Lang, C. Erik Dempfle et al., "High plasma levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and interleukin-8 (IL-8) characterize patients prone to ventricular fibrillation complicatingmyocardial infarction, " Clinical Chemistry and Laboratory Medicine, vol. 45, no. 10, pp. 1360-1365, 2007.
15. J. K. Damas, L. Gullestad, T. Ueland et al., "CXC-chemokines, a new group of cytokines in congestive heart failure-possible role of platelets and monocytes, " Cardiovascular Research, vol. 45, no. 2, pp. 428-436, 2000.
16. A. V. Finsen, T. Ueland, I. Sjaastad et al., "The homeostatic chemokine CCL21 predicts mortality in aortic stenosis patients and modulates left ventricular remodeling, " PLoS ONE, vol. 9, no. 11, Article ID e112172, 2014.
17. T. J. Larocca, D. Jeong, E. Kohlbrenner et al., "CXCR4 gene transfer prevents pressure overload induced heart failure, " Journal of Molecular and Cellular Cardiology, vol. 53, no. 2, pp. 223-232, 2012.
18. A. Waehre, B. Halvorsen, A. Yndestad et al., "Lack of chemokine signaling through CXCR5 causes increased mortality, ventricular dilatation and deranged matrix during cardiac pressure overload, " PLoS ONE, vol. 6, no. 4, Article ID e18668, 2011.
19. A. Waehre, M. Vistnes, I. Sjaastad et al., "Chemokines regulate small leucine-rich proteoglycans in the extracellular matrix of the pressure-overloaded right ventricle, " Journal of Applied Physiology, vol. 112, no. 8, pp. 1372-1382, 2012.
20. L. G. Nogueira, R. H. B. Santos, B. M. Ianni et al., "Myocardial chemokine expression and intensity of myocarditis in Chagas cardiomyopathy are controlled by polymorphisms in CXCL9 and CXCL10, " PLoS Neglected Tropical Diseases, vol. 6, no. 10, Article ID e1867, 2012.
21. W. Xuan, Y. Liao, B. Chen et al., "Detrimental effect of fractalkine on myocardial ischaemia and heart failure, " Cardiovascular Research, vol. 92, no. 3, pp. 385-393, 2011.
22. D. N. Streblow, C. Kreklywich, Q. Yin et al., "Cytomegalovirusmediated upregulation of chemokine expression correlates with the acceleration of chronic rejection in rat heart transplants, " Journal of Virology, vol. 77, no. 3, pp. 2182-2194, 2003.
23. K. A. Reimer and R. B. Jennings, The Heart and Cardiovascular System: Scientific Foundations, vol. 1 of The Heart and Cardiovascular System, Harry Allen Fozzard, Raven Press, New York, NY, USA, 1986.
24. H. K. Hawkins, M. L. Entman, J. Y. Zhu et al., "Acute inflammatory reaction after myocardial ischemic injury and reperfusion. Development and use of a neutrophil-specific antibody, " The American Journal of Pathology, vol. 148, no. 6, pp. 1957-1969, 1996.
25. H. H. Birdsall, D. M. Green, J. Trial et al., "Complement C5a, TGF-1, and MCP-1, in sequence, induce migration of monocytes into ischemic canine myocardium within the first one to five hours after reperfusion, " Circulation, vol. 95, no. 3, pp. 684-692, 1997.
26. L. M. Riou, M. Ruiz, G. W. Sullivan et al., "Assessment of myocardial inflammation produced by experimental coronary occlusion and reperfusion with 99mTc-RP517, a new leukotriene B4 receptor antagonist that preferentially labels neutrophils in vivo, " Circulation, vol. 106, no. 5, pp. 592-598, 2002.
27. L. Calvillo, S. Masson, M. Salio et al., "In vivo cardioprotection by N-acetylcysteine and isosorbide 5-mononitrate in a rat model of ischemia-reperfusion, " Cardiovascular Drugs and Therapy, vol. 17, no. 3, pp. 199-208, 2003.
28. W. Grossman, D. Jones, and L. P. McLaurin, "Wall stress and patterns ofhypertrophy in thehuman leftventricle, "TheJournal of Clinical Investigation, vol. 56, no. 1, pp. 56-64, 1975.
29. H. K. Song, S.-E. Hong, T. Kim, and D. H. Kim, "Deep RNA sequencing reveals novel cardiac transcriptomic signatures for physiological and pathological hypertrophy, " PLoS ONE, vol. 7, no. 4, Article ID e35552, 2012.
30. M. G. St John Sutton and N. Sharpe, "Left ventricular remodeling after myocardial infarction: pathophysiology and therapy, " Circulation, vol. 101, no. 25, pp. 2981-2988, 2000.
31. G. D. Duerr, J. C. Heinemann, S. Dunkel et al., "Myocardial hypertrophy is associated with inflammation and activation of endocannabinoid system in patients with aortic valve stenosis, " Life Sciences, vol. 92, no. 20-21, pp. 976-983, 2013.
32. F. Shang, J. Wang, X. Liu et al., "Involvement of reactive oxygen species and JNK in increased expression of MCP-1 and infiltration of inflammatory cells in pressure-overloaded rat hearts, "MolecularMedicine Reports, vol. 5, no. 6, pp. 1491-1496, 2012.
33. N. Frey, H. A. Katus, E. N. Olson, and J. A. Hill, "Hypertrophy of the heart: a new therapeutic target?" Circulation, vol. 109, no. 13, pp. 1580-1589, 2004.
34. S. C. A. De Jager, B. W. C. Bongaerts, M. Weber et al., "Chemokines CCL3/MIP1, CCL5/RANTES and CCL18/PARC are independent risk predictors of short-term mortality in patients with acute coronary syndromes, " PLoS ONE, vol. 7, no. 9, Article ID e45804, 2012.
35. S. T. Tarzami, R. Cheng, W. Miao, R. N. Kitsis, and J. W. Berman, "Chemokine expression inmyocardial ischemia: MIP-2 dependent MCP-1 expression protects cardiomyocytes from cell death, " Journal ofMolecular and Cellular Cardiology, vol. 34, no. 2, pp. 209-221, 2002.
36. C. Y. Ho, B. López, O. R. Coelho-Filho et al., "Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy, " The New England Journal of Medicine, vol. 363, no. 6, pp. 552-563, 2010.
37. G. Olivetti, J. M. Capasso, E. H. Sonnenblick, and P. Anversa, "Side-to-side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats, " Circulation Research, vol. 67, no. 1, pp. 23-34, 1990.
38. M. Dobaczewski and N. G. Frangogiannis, "Chemokines and cardiac fibrosis, " Frontiers in Bioscience, vol. 1, no. 2, pp. 391-405, 2009.
39. G. Novo, C. Bellia, M. Fiore et al., "A risk score derived from the analysis of a cluster of 27 serum inflammatory cytokines to predict long term outcome in patients with acute myocardial infarction: a pilot study, " Annals of Clinical and Laboratory Science, vol. 45, no. 4, pp. 382-390, 2015.
40. E. Economou, D. Tousoulis, A. Katinioti et al., "Chemokines in patients with ischaemic heart disease and the effect of coronary angioplasty, " International Journal of Cardiology, vol. 80, no. 1, pp. 55-60, 2001.
41. A. Ghigo, I. Franco, F. Morello, and E. Hirsch, "Myocyte signalling in leucocyte recruitment to the heart, " Cardiovascular Research, vol. 102, no. 2, pp. 270-280, 2014.
42. M. Takahashi, C. Galligan, L. Tessarollo, and T. Yoshimura, "Monocyte chemoattractant protein-1 (MCP-1), not MCP-3, is the primary chemokine required for monocyte recruitment in mouse peritonitis induced with thioglycollate or zymosan A, " The Journal of Immunology, vol. 183, no. 5, pp. 3463-3471, 2009.
43. J. A. de Lemos, D. A. Morrow, M. S. Sabatine et al., "Association between plasma levels of monocyte chemoattractant protein-1 and long-termclinical outcomes in patients with acute coronary syndromes, " Circulation, vol. 107, no. 5, pp. 690-695, 2003.
44. T. Kakio, A. Matsumori, K. Ono, H. Ito, K. Matsushima, and S. Sasayama, "Roles and relationship of macrophages and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the ischemic and reperfused rat heart, " Laboratory Investigation, vol. 80, no. 7, pp. 1127-1136, 2000.
45. P. J. Hohensinner, C. Kaun, K. Rychli et al., "Monocyte chemoattractant protein (MCP-1) is expressed in human cardiac cells and is differentially regulated by inflammatory mediators and hypoxia, " FEBS Letters, vol. 580, no. 14, pp. 3532-3538, 2006.
46. M. Bucova, J. Lietava, P. Penz et al., "Association of MCP-1-2518 A/G single nucleotide polymorphism with the serum level of crp in slovak patients with ischemic heart disease, angina pectoris, and hypertension, " Mediators of Inflammation, vol. 2009, Article ID 390951, 6 pages, 2009.
47. N. G. Frangogiannis, O. Dewald, Y. Xia et al., "Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy, " Circulation, vol. 115, no. 5, pp. 584-592, 2007.
48. M. Ishibashi, K.-I. Hiasa, Q. Zhao et al., "Critical role of monocyte chemoattractant protein-1 receptor CCR2 onmonocytes in hypertension-induced vascular inflammation and remodeling, " Circulation Research, vol. 94, no. 9, pp. 1203-1210, 2004.
49. F. Kuwahara, H. Kai, K. Tokuda et al., "Hypertensivemyocardial fibrosis and diastolic dysfunction: another model of inflammation?" Hypertension, vol. 43, no. 4, pp. 739-745, 2004.
50. M. Sopel, A. Falkenham, A. Oxner, I. Ma, T. D. G. Lee, and J.-F. Légaré, "Fibroblast progenitor cells are recruited into the myocardium prior to the development of myocardial fibrosis, " International Journal of Experimental Pathology, vol. 93, no. 2, pp. 115-124, 2012.
51. S. B. Haudek, J. Cheng, J. Du et al., "Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy, " Journal ofMolecular and Cellular Cardiology, vol. 49, no. 3, pp. 499-507, 2010.
52. L. Gullestad, P. Aukrust, T. Ueland et al., "Effect of highversus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure, " Journal of the American College of Cardiology, vol. 34, no. 7, pp. 2061-2067, 1999.
53. H. Morimoto, M. Takahashi, A. Izawa et al., "Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction, " Circulation Research, vol. 99, no. 8, pp. 891-899, 2006.
54. O. Dewald, P. Zymek, K. Winkelmann et al., "CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts, " Circulation Research, vol. 96, no. 8, pp. 881-889, 2005.
55. R. Roberts, V. DeMello, and B. E. Sobel, "Deleterious effects of methylprednisolone in patients with myocardial infarction, " Circulation, vol. 53, no. 3, pp. I-204-I-206, 1976.
56. J. K. Damas, H. G. Eiken, E. Oie et al., "Myocardial expressionof CC-and CXC-chemokines and their receptors in human endstage heart failure, " Cardiovascular Research, vol. 47, no. 4, pp. 778-787, 2000.
57. T. Husebye, J. Eritsl, H. Arnesen et al., "Association of interleukin 8 and myocardial recovery in patients with St-elevation myocardial infarction complicated by acute heart failure, " PLoS ONE, vol. 9, no. 11, Article ID e112359, 2014.
58. B. Chandrasekar, P. C. Melby, H. M. Sarau et al., "Chemokinecytokine cross-talk: the ELR+ CXC chemokine LIX (CXCl5) amplifies a proinflammatory cytokine response via a phosphatidylinositol 3-kinase-NF-B pathway, " The Journal of Biological Chemistry, vol. 278, no. 7, pp. 4675-4686, 2003.
59. E. P. C. van der Vorst, Y. Döring, and C. Weber, "MIF and CXCL12 in cardiovascular diseases: functional differences and similarities, " Frontiers in Immunology, vol. 6, article 373, 2015.
60. J.-F. Wang, Z.-Y. Liu, and J. E. Groopman, "The-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion, " Blood, vol. 92, no. 3, pp. 756-764, 1998.
61. T. J. LaRocca, M. Schwarzkopf, P. Altman et al., "2-adrenergic receptor signaling in the cardiacmyocyte ismodulated by interactions with CXCR4, " Journal of Cardiovascular Pharmacology, vol. 56, no. 5, pp. 548-559, 2010.
62. E. R. Wang, A. A. Jarrah, L. Benard et al., "Deletion of CXCR4 in cardiomyocytes exacerbates cardiac dysfunction following isoproterenol administration, " Gene Therapy, vol. 21, no. 5, pp. 496-506, 2014.
63. P.-Y. Chu, J. Mariani, S. Finch et al., "Bone marrow-derived cells contribute to fibrosis in the chronically failing heart, " The American Journal of Pathology, vol. 176, no. 4, pp. 1735-1742, 2010.
64. L. Li, H. Zeng, and J.-X. Chen, "Apelin-13 increases myocardial progenitor cells and improves repair postmyocardial infarction, " American Journal of Physiology-Heart and Circulatory Physiology, vol. 303, no. 5, pp. H605-H618, 2012.
65. S. Brunner, J. Winogradow, B. C. Huber et al., "Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis, " The FASEB Journal, vol. 23, no. 2, pp. 351-361, 2009.
66. L. Calvillo, R. Latini, J. Kajstura et al., "Recombinant human erythropoietin protects the myocardium from ischemiareperfusion injury and promotes beneficial remodeling, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 8, pp. 4802-4806, 2003.
67. H. Hwang and R. A. Kloner, "The combined administration of multiple soluble factors in the repair of chronically infarcted rat myocardium, " Journal of Cardiovascular Pharmacology, vol. 57, no. 3, pp. 282-286, 2011.
68. B. Schumacher, P. Peecher, B. U. von Specht, and T. Stegmann, "Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease, " Circulation, vol. 97, no. 7, pp. 645-650, 1998.
69. B. Richter, L. Koller, P. J. Hohensinner et al., "Fractalkine is an independent predictor of mortality in patients with advanced heart failure, " Thrombosis and Haemostasis, vol. 108, no. 6, pp. 1220-1227, 2012.
70. S. Y. Ahn, C.-H. Cho, K.-G. Park et al., "Tumor necrosis factor-induces fractalkine expression preferentially in arterial endothelial cells and mithramycin A suppresses TNF-induced fractalkine expression, " The American Journal of Pathology, vol. 164, no. 5, pp. 1663-1672, 2004.
71. A. Yndestad, A. V. Finsen, T. Ueland et al., "The homeostatic chemokineCCL21 predictsmortality and may play a pathogenic role in heart failure, " PLoS ONE, vol. 7, no. 3, Article ID e33038, 2012.
72. P. Sterling and J. Eyer, "Allostasis: a new paradigm to explain arousal pathology, " in Handbook of Life Stress, Cognition, and Health, S. Fisher and J. T. Reason, Eds., John Wiley & Sons, Chichester, NY, USA, 1988.
73. J. A. Armour, D. A. Murphy, B.-X. Yuan, S. Macdonald, and D. A. Hopkins, "Gross and microscopic anatomy of the human intrinsic cardiac nervous system, " Anatomical Record, vol. 247, no. 2, pp. 289-298, 1997.
74. J. A. Armour, "Myocardial ischaemia and the cardiac nervous system, " Cardiovascular Research, vol. 41, no. 1, pp. 41-54, 1999.
75. R. D. Foreman, "Mechanisms of cardiac pain, " Annual Review of Physiology, vol. 61, no. 1, pp. 143-167, 1999.
76. P. Dutta, G. Courties, Y. Wei et al., "Myocardial infarction accelerates atherosclerosis, " Nature, vol. 487, no. 7407, pp. 325-329, 2012.
77. F. Leuschner, P. J. Rauch, T. Ueno et al., "Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullarymonocytopoiesis, " Journal of ExperimentalMedicine, vol. 209, no. 1, pp. 123-137, 2012.
78. L. Fang, X.-L. Moore, A. M. Dart, and L.-M. Wang, "Systemic inflammatory response following acute myocardial infarction, " Journal of Geriatric Cardiology, vol. 12, no. 3, pp. 305-312, 2015.
79. G. Haskó and C. Szabó, "Regulation of cytokine and chemokine production by transmitters and co-transmitters of the autonomic nervous system, " Biochemical Pharmacology, vol. 56, no. 9, pp. 1079-1087, 1998.
80. G. P. Chrousos, F. Epstein, J. Flier, S. Reichlin, and S. Pavlou, "The hypothalamic-pituitary-adrenal axis and immunemediated inflammation, "The New England Journal ofMedicine, vol. 332, no. 20, pp. 1351-1362, 1995.
81. G. Davatelis, S. D. Wolpe, B. Sherry, J.-M. Dayer, R. Chicheportiche, and A. Cerami, "Macrophage inflammatory protein-1: a prostaglandin-independent endogenous pyrogen, " Science, vol. 243, no. 4894, pp. 1066-1068, 1989.
82. J. Shanks and N. Herring, "Peripheral cardiac sympathetic hyperactivity in cardiovascular disease: role of neuropeptides, " American Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 305, no. 12, pp. R1411-R1420, 2013.
83. D. L. Bellinger, B. A. Millar, S. Perez et al., "Sympathetic modulation of immunity: relevance to disease, " Cellular Immunology, vol. 252, no. 1-2, pp. 27-56, 2008.
84. J. Sun, R. D. Ramnath, and M. Bhatia, "Neuropeptide substance P upregulates chemokine and chemokine receptor expression in primary mouse neutrophils, " American Journal of Physiology-Cell Physiology, vol. 293, no. 2, pp. C696-C704, 2007.
85. G. C. Meléndez, E. J. Manteufel, H. M. Dehlin, T. C. Register, and S. P. Levick, "Non-human primate and rat cardiac fibroblasts show similar extracellular matrix-related and cellular adhesion gene responses to substance P, " Heart Lung and Circulation, vol. 24, no. 4, pp. 395-403, 2015.
86. M. L. Castellani, J. Vecchiet, V. Salini et al., "Stimulation ofCCL2 (MCP-1) and CCL2 mRNA by substance P in LAD2 human mast cells, " Translational Research, vol. 154, no. 1, pp. 27-33, 2009.
87. F. Hua, J. L. Ardell, and C. A. Williams, "Left vagal stimulation induces dynorphin release and suppresses substance P release from the rat thoracic spinal cord during cardiac ischemia, " American Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 287, no. 6, pp. R1468-R1477, 2004.
88. L. Calvillo, E. Vanoli, E. Andreoli et al., "Vagal stimulation, through its nicotinic action, limits infarct size and the inflammatory response to myocardial Ischemia and reperfusion, " Journal of Cardiovascular Pharmacology, vol. 58, no. 5, pp. 500-507, 2011.
89. G. M. De Ferrari, H. J. G. M. Crijns, M. Borggrefe et al., "Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure, " European Heart Journal, vol. 32, no. 7, pp. 847-855, 2011.
90. M. Li, C. Zheng, T. Sato, T. Kawada, M. Sugimachi, and K. Sunagawa, "Vagal nerve stimulation markedly improves longtermsurvival after chronic heart failure in rats, " Circulation, vol. 109, no. 1, pp. 120-124, 2004.
91. S. Han, K. Kobayashi, B. Joung et al., "Electroanatomic remodeling of the left stellate ganglion after myocardial infarction, " Journal of theAmericanCollege of Cardiology, vol. 59, no. 10, pp. 954-961, 2012.
92. S. Zhou, L. S. Chen, Y. Miyauchi et al., "Mechanisms of cardiac nerve sprouting aftermyocardial infarction in dogs, " Circulation Research, vol. 95, no. 1, pp. 76-83, 2004.
93. M. Ogawa, S. Zhou, A. Y. Tan et al., "Left stellate ganglion and vagal nerve activity and cardiac arrhythmias in ambulatory dogs with pacing-induced congestive heart failure, " Journal of the American College of Cardiology, vol. 50, no. 4, pp. 335-343, 2007.
94. A. Wood, S. Docimo Jr., and D. E. Elkowitz, "Cardiovascular disease and its association with histological changes of the left stellate ganglion, " Clinical Medicine Insights: Pathology, vol. 3, pp. 19-24, 2010.
95. O. A. Ajijola, J. J. Wisco, H. W. Lambert et al., "Extracardiac neural remodeling in humans with cardiomyopathy, " Circulation: Arrhythmia and Electrophysiology, vol. 5, no. 5, pp. 1010-1016, 2012.
96. O. A. Ajijola, D. Yagishita, N. K. Reddy et al., "Remodeling of stellate ganglion neurons after spatially targeted myocardial infarction: neuropeptide and morphologic changes, " Heart Rhythm, vol. 12, no. 5, pp. 1027-1035, 2015.
97. Y. Wang, D. Zhang, M. Ashraf et al., "Combining neuropeptide Y and mesenchymal stem cells reverses remodeling after myocardial infarction, " American Journal of Physiology-Heart and Circulatory Physiology, vol. 298, no. 1, pp. H275-H286, 2010.
98. M. Meloni, D. Cesselli, A. Caporali et al., "Cardiac nerve growth factor overexpression induces bonemarrow-derived progenitor cellsmobilization and homing to the infarcted heart, "Molecular Therapy, vol. 23, no. 12, pp. 1854-1866, 2015.
99. K. J. Tracey, "The inflammatory reflex, " Nature, vol. 420, no. 6917, pp. 853-859, 2002.
100. T. R. Bernik, S. G. Friedman, M. Ochani et al., "Cholinergic antiinflammatory pathway inhibition of tumor necrosis factor during ischemia reperfusion, " Journal of Vascular Surgery, vol. 36, no. 6, pp. 1231-1236, 2002.
101. H. Li, Z.-Z. Zhang, J. Zhan, X.-H. He, X.-M. Song, and Y.-L. Wang, "Protective effect of PNU-120596, a selective 7 nicotinic acetylcholine receptor-positive allosteric modulator, on myocardial ischemia-reperfusion injury in rats, " Journal of Cardiovascular Pharmacology, vol. 59, no. 6, pp. 507-513, 2012.
102. C. Leib, S. Göser, D. Lüthje et al., "Role of the cholinergic antiinflammatory pathway in murine autoimmune myocarditis, " Circulation Research, vol. 109, no. 2, pp. 130-140, 2011.
103. P. M. Vanhoutte and M. N. Levy, "Prejunctional cholinergic modulation of adrenergic neurotransmission in the cardiovascular system, " The American Journal of Physiology, vol. 238, no. 3, pp. H275-H281, 1980.
104. E. Vanoli, P. B. Adamson, R. D. Foreman, and P. J. Schwartz, "Prediction of unexpected sudden death among healthy dogs by a novel marker of autonomic neural activity, " Heart Rhythm, vol. 5, no. 2, pp. 300-305, 2008.
105. M. T. La Rovere, J. T. Bigger Jr., F. I. Marcus, A. Mortara, and P. J. Schwartz, "Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction, " The Lancet, vol. 351, no. 9101, pp. 478-484, 1998.
106. M. T. La Rovere, G. D. Pinna, S. H. Hohnloser et al., "Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials, " Circulation, vol. 103, no. 16, pp. 2072-2077, 2001.
107. G. M. De Ferrari, A. Sanzo, G. M. Castelli et al., "Rapid recovery of baroreceptor reflexes in acute myocardial infarction is a marker of effective tissue reperfusion, " Journal of Cardiovascular Translational Research, vol. 7, no. 6, pp. 553-559, 2014.
108. T. E. Nelson and D. L. Gruol, "The chemokine CXCL10 modulates excitatory activity and intracellular calcium signaling in cultured hippocampal neurons, " Journal of Neuroimmunology, vol. 156, no. 1-2, pp. 74-87, 2004.
109. P. J. Schwartz, E. H. Locati, A. J. Moss, R. S. Crampton, R. Trazzi, and U. Ruberti, "Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome: a worldwide report, " Circulation, vol. 84, no. 2, pp. 503-511, 1991.
110. G. M. De Ferrari, V. Dusi, C. Spazzolini et al., "Clinical management of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation, " Circulation, vol. 131, no. 25, pp. 2185-2193, 2015.
111. S. Rizzo, C. Basso, D. Troost et al., "T-cell-mediated inflammatory activity in the stellate ganglia of patients with ionchannel disease and severe ventricular arrhythmias, " Circulation: Arrhythmia and Electrophysiology, vol. 7, no. 2, pp. 224-229, 2014.
112. B. P. Scicluna, C. A. Remme, M. Rivaud, A. A. M. Wilde, C. R. Bezzina, and A. O. Verkerk, "Chemokine ligand 9 modulates cardiac repolarization via Cxcr3 receptor binding, " International Journal of Cardiology, vol. 201, pp. 49-52, 2015.
113. A. Asimaki, H. Tandri, E. R. Duffy et al., "Altered desmosomal proteins in granulomatous myocarditis and potential pathogenic links to arrhythmogenic right ventricular cardiomyopathy, " Circulation: Arrhythmia and Electrophysiology, vol. 4, no. 5, pp. 743-752, 2011.
114. N. Wu, B. Xu, Y. Xiang et al., "Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis, " International Journal of Cardiology, vol. 169, no. 1, pp. 62-72, 2013.
115. J. M. Alegret, G. Aragonès, R. Elosua et al., "The relevance of the association between inflammation and atrial fibrillation, " European Journal of Clinical Investigation, vol. 43, no. 4, pp. 324-331, 2013.
116. I. Liuba, H. Ahlmroth, L. Jonasson et al., "Source of inflammatory markers in patients with atrial fibrillation, " Europace, vol. 10, no. 7, pp. 848-853, 2008.
117. Y. Guo, S. Apostalakis, A. D. Blann, and G. Y. H. Lip, "Plasma CX3CL1 levels and long term outcomes of patients with atrial fibrillation: the West Birmingham Atrial Fibrillation Project, " Cerebrovascular Diseases, vol. 38, no. 3, pp. 204-211, 2014.
118. B. J. Maron, J. A. Towbin, G. Thiene et al., "Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology InterdisciplinaryWorking Groups; and Council on Epidemiology and Prevention, " Circulation, vol. 113, no. 14, pp. 1807-1816, 2006.
119. J. M. Hare, "The etiologic basis of congestive heart failure, " in Atlas of Heart Failure, pp. 33-60, Springer, 2004.
120. R. E. Hershberger, A. Morales, and J. D. Siegfried, "Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals, " Genetics in Medicine, vol. 12, no. 11, pp. 655-667, 2010.
121. S. W. Sharkey, B. J. Maron, P. Nelson, M. Parpart, M. S. Maron, and M. R. Bristow, "Adrenergic receptor polymorphisms in patients with stress (tako-tsubo) cardiomyopathy, " Journal of Cardiology, vol. 53, no. 1, pp. 53-57, 2009.
122. P. Muir, F. Nicholson, A. J. Tilzey, M. Signy, T. A. English, and J. E. Banatvala, "Chronic relapsing pericarditis and dilated cardiomyopathy: serological evidence of persistent enterovirus infection, " The Lancet, vol. 1, no. 8642, pp. 804-807, 1989.
123. A. L. P. Caforio, P. J. Keeling, W. J. McKenna et al., "Evidence from family studies for autoimmunity in dilated cardiomyopathy, " The Lancet, vol. 344, no. 8925, pp. 773-777, 1994.
124. L. S. Lilly, Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, vol. 1, Elsevier Health Sciences, 2012.
125. A. F. Frade, C. W. Pissetti, B. M. Ianni et al., "Genetic susceptibility to Chagas disease cardiomyopathy: involvement of several genes of the innate immunity and chemokine-dependent migration pathways, " BMC Infectious Diseases, vol. 13, p. 587, 2013.
126. A. M. B. Bilate and E. Cunha-Neto, "Chagas disease cardiomyopathy: current concepts of an old disease, " Revista do Instituto deMedicina Tropical de São Paulo, vol. 50, no. 2, pp. 67-74, 2008.
127. P. M. M. Guedes, F. R. S. Gutierrez, G. K. Silva et al., "Deficient regulatory T cell activity and low frequency of IL-17-producing T cells correlate with the extent of cardiomyopathy in human Chagas' disease, " PLoS Neglected Tropical Diseases, vol. 6, no. 4, Article ID e1630, 2012.
128. E. Cunha-Neto and C. Chevillard, "Chagas disease cardiomyopathy: immunopathology and genetics, " Mediators of Inflammation, vol. 2014, Article ID 683230, 11 pages, 2014.
129. P. R. Luz, M. I. Miyazaki, N. Chiminacio Neto et al., "Genetically determined MBL deficiency is associated with protection against chronic cardiomyopathy in Chagas disease, " PLoS Neglected Tropical Diseases, vol. 10, no. 1, Article ID e0004257, 2016.
130. O. Flórez, J. Martín, and C. I. González, "Genetic variants in the chemokines and chemokine receptors in Chagas disease, " Human Immunology, vol. 73, no. 8, pp. 852-858, 2012.
131. Y. Seino, U. Ikeda, H. Sekiguchi et al., "Expression of leukocyte chemotactic cytokines inmyocardial tissue, " Cytokine, vol. 7, no. 3, pp. 301-304, 1995.
132. P. E. Kolattukudy, T. Quach, S. Bergese et al., "Myocarditis induced by targeted expression of the MCP-1 gene in murine cardiac muscle, " American Journal of Pathology, vol. 152, no. 1, pp. 101-111, 1998.
133. M. H. Lehmann, H. Kühnert, S. Müller, and H. H. Sigusch, "Monocyte chemoattractant protein 1 (MCP-1) gene expression in dilated cardiomyopathy, " Cytokine, vol. 10, no. 10, pp. 739-746, 1998.
134. M. Kobayashi, K. Nakamura, K. F. Kusano et al., "Expression of monocyte chemoattractant protein-1 in idiopathic dilated cardiomyopathy, " International Journal of Cardiology, vol. 126, no. 3, pp. 427-429, 2008.
135. S. Göser, R. öttl, A. Brodner et al., "Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 in induction of experimental autoimmunemyocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy, " Circulation, vol. 112, no. 22, pp. 3400-3407, 2005.
136. J. Guo, H. Zhang, J. Xiao et al., "Monocyte chemotactic protein-1 promotes the myocardial homing of mesenchymal stem cells in dilated cardiomyopathy, " International Journal of Molecular Sciences, vol. 14, no. 4, pp. 8164-8178, 2013.
137. K. Bachmaier, S. Toya, and A. B. Malik, "Therapeutic administration of the chemokine CXCL1/KC abrogates autoimmune inflammatory heart disease, " PLoS ONE, vol. 9, no. 2, Article ID e89647, 2014.
138. L. C. L. Correia, B. B. Andrade, V. M. Borges et al., "Prognostic value of cytokines and chemokines in addition to the GRACE Score in non-ST-elevation acute coronary syndromes, " Clinica Chimica Acta, vol. 411, no. 7-8, pp. 540-545, 2010.